If you liked this article you might like

Bristol-Myers Buys Back Shares, Shuffles Board
Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
Biotech Buoyed by Deal Talk
Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment